Listed by the USPTO as PETRASH, HILARY ANN
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 66% of resolved cases
PETRASH, HILARY ANN is assigned to tech center 1600 and art unit 1641. The profile records 64 resolved cases, a 65.6% allowance rate, and a median of 1161 days to allowance. The interview lift is 50.2%, indicating a strong positive association between interviews and allowance outcomes in the available record.
Adc Therapeutics SA, Janssen Pharmaceuticals Inc., and ImmunityBio Inc. are the leading listed companies. The listed firms are MEDLER FERRO WOODHOUSE & MILLS PLLC, BIRCH STEWART KOLASCH & BIRCH, LLP, and Birchwood IP- CHK001. The limited case history warrants caution in projecting outcomes, but the interview measure supports careful preparation for direct examiner discussions.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17539926 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA | Final Rejection | TEIJIN PHARMA LIMITED |
| 17491813 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18415188 | COMPOSITIONS AND METHODS FOR TREATING ACUTE MYELOID LEUKEMIA | Non-Final OA | Wuhan University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy65.6% of resolved applications examined by Hilary Ann Petrash were allowed (64 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +50.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Hilary Ann Petrash took 1,161 days on average from filing to allowance.
Hilary Ann Petrash examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
